Evaxion Biotech A/S

Clinical trials sponsored by Evaxion Biotech A/S, explained in plain language.

Evaxion Biotech A/S EVAX NASDAQ

Develops AI-driven immunotherapies for cancer and infectious diseases.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Not yet finished but already full! 1

New combo shows promise against tough skin cancer

Disease control Ongoing

This phase 2 trial tests whether adding an experimental drug (EVX-01) to standard immunotherapy (pembrolizumab) can shrink tumors better than pembrolizumab alone in people with advanced melanoma that cannot be removed by surgery. Seventeen adults who have never received checkpoin…

Phase 2 • Sponsor: Evaxion Biotech A/S • Aim: Disease control

Last updated Jun 27, 2026 07:51 UTC

Evaxion Biotech A/S

New combo shows promise against tough skin cancer